

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

THE PHASE III CLINICAL STUDY OF HS-10374 IN THE TREATMENT OF MODERATE-TO-SEVERE PLAQUE PSORIASIS HAS MET THE CO-PRIMARY ENDPOINTS

The board of directors (the “**Board**”) of Hansoh Pharmaceutical Group Company Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) is pleased to announce that HS-10374, a selective allosteric inhibitor of tyrosine kinase 2 (“**TYK2**”) self-developed by the Group, met the co-primary endpoints in the pivotal Phase III clinical trial for adults with moderate-to-severe plaque psoriasis. At week 16 of treatment, the proportion of participants in the HS-10374 group achieving at least a 75% reduction (PASI 75) from baseline in the Psoriasis Area and Severity Index (“**PASI**”) and the proportion achieving a static Physician's Global Assessment (“**sPGA**”) score of 0 or 1 with at least a 2-point improvement from baseline (sPGA 0/1) were both significantly higher than those in the placebo group. The trial also met multiple secondary endpoints. More than half of the HS-10374-treated participants achieved PASI 90, and almost one-third achieved PASI 100 at week 16. Meanwhile, HS-10374 demonstrated a favorable safety and tolerability profile, which was consistent with that of other TYK2 inhibitors, and no new safety signals were observed.

Based on these positive results, the Group will initiate communications with the relevant regulatory authority to advance preparations for new drug application in China in the near term. The results are scheduled to be presented at an upcoming academic conference in the dermatology therapeutic area.

By Order of the Board
Hansoh Pharmaceutical Group Company Limited
Zhong Huijuan
Chairlady

Hong Kong, September 21, 2026

As at the date of this announcement, the Board comprises Ms. Zhong Huijuan as chairlady and executive director, Ms. Sun Yuan and Dr. Lyu Aifeng as executive directors, and Mr. Lin Guoqiang, Mr. Chan Charles Sheung Wai, Ms. Yang Dongtao and Mr. Yan Jia as independent non-executive directors.